Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2006

01-08-2006 | Concise Article

Addition of a macrolide to a ß-lactam in bacteremic pneumococcal pneumonia

Authors: R. Dwyer, Å. Örtqvist, E. Aufwerber, B. Henriques Normark, T.J. Marrie, M.A. Mufson, A. Torres, M.A. Woodhead, M. Ålenius, M. Kalin

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2006

Login to get access

Abstract

In the study presented here, data collected prospectively from 340 adult patients hospitalised in five countries with bacteremic pneumococcal CAP and treated with a ß-lactam +/− a macrolide were analysed retrospectively to evaluate the efficacy of this antimicrobial combination. Univariate and multivariate analyses revealed no significant effect on case fatality rate when a macrolide/ß-lactam regimen was used as initial therapy. Results were not affected by severity of illness, or by excluding patients who died within 2 days of admission. Identified predictors of death in a multivariate regression model were age >65 years (OR=2.6), two or more lung lobes affected (OR=2.2), and severity of disease as estimated using the acute physiology score (APS)>8.
Literature
1.
Kalin M, Örtqvist Å, Almela M et al (2000) Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 182:840–847PubMedCrossRef
2.
Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 31:347–382PubMedCrossRef
3.
Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ (1999) Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumoniae. Arch Intern Med 159:2562–2572PubMedCrossRef
4.
Dudas V, Hopefl A, Jacobs R, Guglielmo JB (2000) Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 34:446–452PubMedCrossRef
5.
Houck PM, MacLehose RF, Niederman MS, Lowery JK (2001) Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states. Chest 119:1420–1426PubMedCrossRef
6.
Brown RB, Iannini P, Gross P, Kunkel M (2003) Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia. Chest 123:1503–1511PubMedCrossRef
7.
Mufson MA, Stanek RJ (1999) Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study. Am J Med 107(Suppl 1A):34–43CrossRef
8.
Martinez JA, Horcajada JP, Almela M et al (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389–395PubMedCrossRef
9.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRef
10.
Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D (2005) Lack of effect of combination therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 24:688–690PubMedCrossRef
11.
Waterer GW, Somes GW, Wunderink RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842PubMedCrossRef
12.
Baddour LM, Yu VL, Klugman KP, Feldman C et al (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:440–444PubMedCrossRef
13.
File TM, Mandell LA (2003) What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Editorial commentary. Clin Infect Dis 36:396–397PubMedCrossRef
14.
Tan MJ, Tan JS, File M (2002) Legionnaires disease with bacteremic coinfection. Clin Infect Dis 35:533–539PubMedCrossRef
15.
Henriques Normark B, Normark S (2002) Antibiotic tolerance in pneumococci. Clin Microbiol Infect 8:613–622PubMedCrossRef
16.
Lin E, Stanek RJ, Mufson MA (2003) Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 47:1151–1153PubMedCrossRef
17.
Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Möller N (2000) Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 46:973–980PubMedCrossRef
Metadata
Title
Addition of a macrolide to a ß-lactam in bacteremic pneumococcal pneumonia
Authors
R. Dwyer
Å. Örtqvist
E. Aufwerber
B. Henriques Normark
T.J. Marrie
M.A. Mufson
A. Torres
M.A. Woodhead
M. Ålenius
M. Kalin
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-006-0183-2

Other articles of this Issue 8/2006

European Journal of Clinical Microbiology & Infectious Diseases 8/2006 Go to the issue

Article

Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies

Brief Report

Prenatal culture-based screening of Streptococcus agalactiae colonisation: resistance against erythromycin and clindamycin

Announcements

Announcements

Brief Report

Serological evidence of human infection with rickettsial strain Bar29 in Catalonia, northeastern Spain

Concise Article

Carriage of Streptococcus pneumoniae in healthy Norwegian children attending day-care centres

Concise Article

Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits